NovaBay Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . NovaBay Pharmaceuticals
NBY Stock  USD 0.64  0.01  1.59%   
NovaBay Pharmaceuticals financial statements provide useful quarterly and yearly information to potential NovaBay Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on NovaBay Pharmaceuticals financial statements helps investors assess NovaBay Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting NovaBay Pharmaceuticals' valuation are summarized below:
Gross Profit
7.9 M
Profit Margin
(0.73)
Market Capitalization
3.1 M
Enterprise Value Revenue
0.2579
Revenue
13.8 M
We have found one hundred twenty available fundamental ratios for NovaBay Pharmaceuticals, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of NovaBay Pharmaceuticals last-minute market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 939.4 K in 2025. Enterprise Value is likely to drop to about 513.3 K in 2025

NovaBay Pharmaceuticals Total Revenue

9.97 Million

Check NovaBay Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NovaBay Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 229.5 K, Interest Expense of 4.6 M or Other Operating Expenses of 16.9 M, as well as many indicators such as Price To Sales Ratio of 0.0638, Dividend Yield of 0.0 or PTB Ratio of 0.28. NovaBay financial statements analysis is a perfect complement when working with NovaBay Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of NovaBay Pharmaceuticals Correlation against competitors.
For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.

NovaBay Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets14.4 M10.4 M12.5 M
Pretty Stable
Other Assets461.6 K562.4 K470.6 K
Pretty Stable
Common Stock Shares Outstanding125.5 K138.5 K159.7 K
Pretty Stable
Liabilities And Stockholders Equity14.4 M10.4 M12.5 M
Pretty Stable
Other Stockholder Equity212.6 M202.5 M115.5 M
Slightly volatile
Total Liabilities7.1 M6.6 M6.7 M
Pretty Stable
Other Current Liabilities1.3 M1.7 M1.3 M
Pretty Stable
Total Current Liabilities4.1 M4.9 M3.8 M
Slightly volatile
Property Plant And Equipment Net1 M1.6 M839.8 K
Slightly volatile
Accounts Payable812.7 K1.3 M909.9 K
Very volatile
Cash2.7 M2.8 M6.1 M
Slightly volatile
Non Current Assets Total2 M2.2 M2 M
Slightly volatile
Cash And Short Term Investments2.7 M2.8 M7 M
Slightly volatile
Common Stock Total Equity263.6 K480.7 K304.7 K
Slightly volatile
Other Current Assets463.4 K446.2 K430.9 K
Pretty Stable
Property Plant And Equipment Gross2.5 M2.4 M1.1 M
Slightly volatile
Total Current Assets9.5 M6.4 M10.4 M
Pretty Stable
Common Stock122.4 K128.8 K273.1 K
Very volatile
Property Plant Equipment1.8 M1.8 M859.5 K
Slightly volatile
Other Liabilities12.2 M11.6 M6.1 M
Slightly volatile
Current Deferred Revenue1.2 M851.4 K1.3 M
Very volatile
Non Current Liabilities Total1.2 M1.3 M3.2 M
Slightly volatile
Short and Long Term Debt Total3.3 M3.2 M2.3 M
Slightly volatile
Non Currrent Assets Other300 K571.5 K299.3 K
Slightly volatile
Net Receivables1.7 M872.9 K1.6 M
Very volatile
Capital Surpluse118.8 M189.8 M111.1 M
Slightly volatile
Non Current Liabilities Other285.6 K300.6 K1.6 M
Slightly volatile
Short and Long Term Debt1.1 M1 M1.6 M
Slightly volatile
Cash And Equivalents7.5 M6.2 M7.7 M
Slightly volatile
Net Invested Capital2.7 M2.9 M4.2 M
Slightly volatile
Net Working Capital3.1 M3.3 M4.9 M
Pretty Stable
Capital Stock1.4 M2.4 M804.1 K
Slightly volatile
Capital Lease Obligations1.3 M1.8 M1.4 M
Very volatile

NovaBay Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization229.5 K233.4 K201.7 K
Very volatile
Other Operating Expenses16.9 M22.7 M18.4 M
Slightly volatile
Research Development58.1 K61.2 K3.1 M
Slightly volatile
Total Operating Expenses15 M14.8 M15.8 M
Very volatile
Selling General Administrative7.5 M7.3 M7.3 M
Very volatile
Total Revenue10 M16.9 M9.5 M
Slightly volatile
Gross Profit8.1 M9.1 M7 M
Slightly volatile
Cost Of Revenue4.7 M6.1 M4 M
Very volatile
Selling And Marketing Expenses7 M5.8 M6.7 M
Slightly volatile
Interest Income2.9 M4.7 M2.7 M
Slightly volatile
Reconciled Depreciation212.9 K317.4 K159.4 K
Slightly volatile
Preferred Stock And Other Adjustments640 K720 K785 K
Slightly volatile

NovaBay Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow6.2 M5.3 M7.3 M
Pretty Stable
Other Cashflows From Financing Activities419.5 K441.6 K5.2 M
Very volatile
Depreciation180.3 K182.7 K205.2 K
Pretty Stable
Capital Expenditures16.2 K17.1 K89.5 K
Slightly volatile
Total Cash From Financing Activities2.1 M2.2 M7.7 M
Pretty Stable
End Period Cash Flow6.1 M3.2 M6.5 M
Pretty Stable
Stock Based Compensation248.8 K261.9 K906.9 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.06380.067148.2626
Slightly volatile
PTB Ratio0.280.361.503
Slightly volatile
Days Sales Outstanding16.0816.9354.6668
Slightly volatile
Book Value Per Share30.0631.65227
Slightly volatile
Stock Based Compensation To Revenue0.02160.02270.1681
Slightly volatile
Capex To Depreciation0.10.110.6675
Slightly volatile
PB Ratio0.280.361.503
Slightly volatile
Inventory Turnover2.122.142.3009
Slightly volatile
Days Of Inventory On Hand324177384
Slightly volatile
Payables Turnover3.225.443.5579
Slightly volatile
Sales General And Administrative To Revenue0.470.491.3308
Slightly volatile
Research And Ddevelopement To Revenue0.0050.00531.196
Slightly volatile
Capex To Revenue0.00140.00150.0285
Slightly volatile
Cash Per Share28.3929.89279
Slightly volatile
Days Payables Outstanding65.9669.444.3 K
Slightly volatile
Income Quality0.510.390.7913
Slightly volatile
Net Debt To EBITDA0.08880.09340.6765
Slightly volatile
Current Ratio1.831.923.4145
Slightly volatile
Tangible Book Value Per Share30.0631.65275
Very volatile
Receivables Turnover18.3317.468.2589
Slightly volatile
Shareholders Equity Per Share30.0631.65227
Slightly volatile
Capex Per Share0.170.188.7455
Slightly volatile
Revenue Per Share134141692
Slightly volatile
Interest Debt Per Share24.8626.17192
Slightly volatile
Debt To Assets0.290.270.2593
Pretty Stable
Graham Number8891 K1.1 K
Slightly volatile
Operating Cycle323198306
Pretty Stable
Price Book Value Ratio0.280.361.503
Slightly volatile
Days Of Payables Outstanding65.9669.444.3 K
Slightly volatile
Ebt Per Ebit1.821.731.1991
Slightly volatile
Quick Ratio1.091.153.0946
Slightly volatile
Net Income Per E B T0.841.381.094
Slightly volatile
Cash Ratio0.80.842.1287
Slightly volatile
Days Of Inventory Outstanding324177384
Slightly volatile
Days Of Sales Outstanding16.0816.9354.6668
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.161.0316
Slightly volatile
Price To Book Ratio0.280.361.503
Slightly volatile
Fixed Asset Turnover11.169.5815.4536
Pretty Stable
Debt Ratio0.290.270.2593
Pretty Stable
Price Sales Ratio0.06380.067148.2626
Slightly volatile
Asset Turnover1.541.470.8396
Slightly volatile
Gross Profit Margin0.80.620.764
Slightly volatile
Price Fair Value0.280.361.503
Slightly volatile

NovaBay Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap939.4 K988.8 K200.2 M
Slightly volatile

NovaBay Fundamental Market Drivers

Cash And Short Term Investments3.1 M

NovaBay Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About NovaBay Pharmaceuticals Financial Statements

NovaBay Pharmaceuticals investors use historical fundamental indicators, such as NovaBay Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NovaBay Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue851.4 K1.2 M
Total Revenue16.9 M10 M
Cost Of Revenue6.1 M4.7 M
Stock Based Compensation To Revenue 0.02  0.02 
Sales General And Administrative To Revenue 0.49  0.47 
Research And Ddevelopement To Revenue 0.01  0.01 
Revenue Per Share 140.62  133.59 
Ebit Per Revenue(0.31)(0.32)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce

Additional Tools for NovaBay Stock Analysis

When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY